Trials / Withdrawn
WithdrawnNCT06926985
An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy
An Exploratory Clinical Study of the Safety and Efficacy of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy
- Status
- Withdrawn
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Jieyang People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A single arm, open-label pilot study is designed to evaluate the safety and effectiveness of anti-CD19/BCMA CAR NK cells (KN5601) in patients with IgA nephropathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-CD19/BCMA CAR NK cells | Patients will receive Fludarabine and Cyclophosphamide on day -5, -4, and -3. Multiple doses of anti-CD19/ BCMA CAR NK cells will infused using the dose-escalation strategy. |
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2026-04-30
- Completion
- 2027-04-30
- First posted
- 2025-04-15
- Last updated
- 2025-07-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06926985. Inclusion in this directory is not an endorsement.